Targeted ablation of the phospholainban gene is associated with markedly enhanced myocardial contractility and loss of β-agonist stimulation

Wusheng Luo, Ingrid L. Grupp, Judy Harrer, Sathivel Ponniah, Gunter Grupp, John J. Duffy, Thomas C Doetschman, Evangelia G. Kranias

Research output: Contribution to journalArticle

592 Citations (Scopus)

Abstract

Phospholamban is the regulator of the Ca2+-ATPase in cardiac sarcoplasmic reticulum (SR), and it has been suggested to be an important determinant in the inotropic responses of the heart to β-adrenergic stimulation. To determine the role of phospholamban in vivo, the gene coding for this protein was targeted in murine embryonic stem cells, and mice deficient in phospholamban were generated. The phospholamban-deficient mice showed no gross developmental abnormalities but exhibited enhanced myocardial performance without changes in heart rate. The time to peak pressure and the time to half-relaxation were significantly shorter in phospholamban-deficient mice compared with their wild-type homozygous littermates as assessed in work-performing mouse heart preparations under identical venous returns, afterloads, and heart rates. The first derivatives of intraventricular pressure (±dP/dt) were also significantly elevated, and this was associated with an increase in the affinity of the SR Ca2+-ATPase for Ca2+ in the phospholamban-deficient hearts. Baseline levels of these parameters in the phospholamban-deficient hearts were equal to those observed in hearts of wild-type littermates maximally stimulated with the β-agonist isoproterenol. These findings indicate that phospholamban acts as a critical repressor of basal myocardial contractility and may be the key phosphoprotein in mediating the heart's contractile responses to β-adrenergic agonists.

Original languageEnglish (US)
Pages (from-to)401-409
Number of pages9
JournalCirculation Research
Volume75
Issue number3
StatePublished - Sep 1994
Externally publishedYes

Fingerprint

Genes
Calcium-Transporting ATPases
Sarcoplasmic Reticulum
Heart Rate
Adrenergic Agonists
phospholamban
Phosphoproteins
Ventricular Pressure
Isoproterenol
Adrenergic Agents
Pressure
Proteins

Keywords

  • β-agonists
  • Cardiac contractility
  • Gene targeting
  • Phospholamban
  • Sarcoplasmic reticulum

ASJC Scopus subject areas

  • Physiology
  • Cardiology and Cardiovascular Medicine

Cite this

Luo, W., Grupp, I. L., Harrer, J., Ponniah, S., Grupp, G., Duffy, J. J., ... Kranias, E. G. (1994). Targeted ablation of the phospholainban gene is associated with markedly enhanced myocardial contractility and loss of β-agonist stimulation. Circulation Research, 75(3), 401-409.

Targeted ablation of the phospholainban gene is associated with markedly enhanced myocardial contractility and loss of β-agonist stimulation. / Luo, Wusheng; Grupp, Ingrid L.; Harrer, Judy; Ponniah, Sathivel; Grupp, Gunter; Duffy, John J.; Doetschman, Thomas C; Kranias, Evangelia G.

In: Circulation Research, Vol. 75, No. 3, 09.1994, p. 401-409.

Research output: Contribution to journalArticle

Luo, Wusheng ; Grupp, Ingrid L. ; Harrer, Judy ; Ponniah, Sathivel ; Grupp, Gunter ; Duffy, John J. ; Doetschman, Thomas C ; Kranias, Evangelia G. / Targeted ablation of the phospholainban gene is associated with markedly enhanced myocardial contractility and loss of β-agonist stimulation. In: Circulation Research. 1994 ; Vol. 75, No. 3. pp. 401-409.
@article{0c7671037f354b40bc68ccebcc3eb7ef,
title = "Targeted ablation of the phospholainban gene is associated with markedly enhanced myocardial contractility and loss of β-agonist stimulation",
abstract = "Phospholamban is the regulator of the Ca2+-ATPase in cardiac sarcoplasmic reticulum (SR), and it has been suggested to be an important determinant in the inotropic responses of the heart to β-adrenergic stimulation. To determine the role of phospholamban in vivo, the gene coding for this protein was targeted in murine embryonic stem cells, and mice deficient in phospholamban were generated. The phospholamban-deficient mice showed no gross developmental abnormalities but exhibited enhanced myocardial performance without changes in heart rate. The time to peak pressure and the time to half-relaxation were significantly shorter in phospholamban-deficient mice compared with their wild-type homozygous littermates as assessed in work-performing mouse heart preparations under identical venous returns, afterloads, and heart rates. The first derivatives of intraventricular pressure (±dP/dt) were also significantly elevated, and this was associated with an increase in the affinity of the SR Ca2+-ATPase for Ca2+ in the phospholamban-deficient hearts. Baseline levels of these parameters in the phospholamban-deficient hearts were equal to those observed in hearts of wild-type littermates maximally stimulated with the β-agonist isoproterenol. These findings indicate that phospholamban acts as a critical repressor of basal myocardial contractility and may be the key phosphoprotein in mediating the heart's contractile responses to β-adrenergic agonists.",
keywords = "β-agonists, Cardiac contractility, Gene targeting, Phospholamban, Sarcoplasmic reticulum",
author = "Wusheng Luo and Grupp, {Ingrid L.} and Judy Harrer and Sathivel Ponniah and Gunter Grupp and Duffy, {John J.} and Doetschman, {Thomas C} and Kranias, {Evangelia G.}",
year = "1994",
month = "9",
language = "English (US)",
volume = "75",
pages = "401--409",
journal = "Circulation Research",
issn = "0009-7330",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - Targeted ablation of the phospholainban gene is associated with markedly enhanced myocardial contractility and loss of β-agonist stimulation

AU - Luo, Wusheng

AU - Grupp, Ingrid L.

AU - Harrer, Judy

AU - Ponniah, Sathivel

AU - Grupp, Gunter

AU - Duffy, John J.

AU - Doetschman, Thomas C

AU - Kranias, Evangelia G.

PY - 1994/9

Y1 - 1994/9

N2 - Phospholamban is the regulator of the Ca2+-ATPase in cardiac sarcoplasmic reticulum (SR), and it has been suggested to be an important determinant in the inotropic responses of the heart to β-adrenergic stimulation. To determine the role of phospholamban in vivo, the gene coding for this protein was targeted in murine embryonic stem cells, and mice deficient in phospholamban were generated. The phospholamban-deficient mice showed no gross developmental abnormalities but exhibited enhanced myocardial performance without changes in heart rate. The time to peak pressure and the time to half-relaxation were significantly shorter in phospholamban-deficient mice compared with their wild-type homozygous littermates as assessed in work-performing mouse heart preparations under identical venous returns, afterloads, and heart rates. The first derivatives of intraventricular pressure (±dP/dt) were also significantly elevated, and this was associated with an increase in the affinity of the SR Ca2+-ATPase for Ca2+ in the phospholamban-deficient hearts. Baseline levels of these parameters in the phospholamban-deficient hearts were equal to those observed in hearts of wild-type littermates maximally stimulated with the β-agonist isoproterenol. These findings indicate that phospholamban acts as a critical repressor of basal myocardial contractility and may be the key phosphoprotein in mediating the heart's contractile responses to β-adrenergic agonists.

AB - Phospholamban is the regulator of the Ca2+-ATPase in cardiac sarcoplasmic reticulum (SR), and it has been suggested to be an important determinant in the inotropic responses of the heart to β-adrenergic stimulation. To determine the role of phospholamban in vivo, the gene coding for this protein was targeted in murine embryonic stem cells, and mice deficient in phospholamban were generated. The phospholamban-deficient mice showed no gross developmental abnormalities but exhibited enhanced myocardial performance without changes in heart rate. The time to peak pressure and the time to half-relaxation were significantly shorter in phospholamban-deficient mice compared with their wild-type homozygous littermates as assessed in work-performing mouse heart preparations under identical venous returns, afterloads, and heart rates. The first derivatives of intraventricular pressure (±dP/dt) were also significantly elevated, and this was associated with an increase in the affinity of the SR Ca2+-ATPase for Ca2+ in the phospholamban-deficient hearts. Baseline levels of these parameters in the phospholamban-deficient hearts were equal to those observed in hearts of wild-type littermates maximally stimulated with the β-agonist isoproterenol. These findings indicate that phospholamban acts as a critical repressor of basal myocardial contractility and may be the key phosphoprotein in mediating the heart's contractile responses to β-adrenergic agonists.

KW - β-agonists

KW - Cardiac contractility

KW - Gene targeting

KW - Phospholamban

KW - Sarcoplasmic reticulum

UR - http://www.scopus.com/inward/record.url?scp=0027932798&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027932798&partnerID=8YFLogxK

M3 - Article

C2 - 8062415

AN - SCOPUS:0027932798

VL - 75

SP - 401

EP - 409

JO - Circulation Research

JF - Circulation Research

SN - 0009-7330

IS - 3

ER -